Effectiveness of Lu177-PSMA in treatment of refractory thyroid papillary cancer.
Phase 2
- Conditions
- radio-iodine refractory papillary thyroid cancer.
- Registration Number
- IRCT20230803059015N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Patients with metastatic radio-iodine refractory papillary thyroid cancer
Patients with baseline, WBC>3000, Hb>9, platelete .cont>70000, AST and ALT<5*nl limit and Cr<2*nl limit
Exclusion Criteria
Patients who refused to participate in the study
Life-expectancy of <1 month
History of other concomittant cancer or other end-stage organ disease
Patients with baseline, WBC<3000, Hb<9, platelete .cont<70000, AST and ALT>5*nl limit and Cr>2*nl limit
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum thyroglobulin level. Timepoint: Monthly. Method of measurement: Blood sampling.;PSMA avid lesions. Timepoint: Before and after completing the treatment. Method of measurement: Diagnostic method with ??Ga-PSMA PET/CT or alternative imaging (Tc??m-PSMA).
- Secondary Outcome Measures
Name Time Method